Daniel L. Simmons
Daniel L. Simmons is a professor of chemistry and the director of the Cancer Research Center at Brigham Young University (BYU). He was the discoverer of the COX-2 enzyme that is the target of celecoxib (Celebrex) and other COX-2 inhibitors. He and BYU felt that Pfizer had not properly credited or paid them for Simmons work in this development and brought a suit against Pfizer.
- Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (April 1991). "Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing". Proceedings of the National Academy of Sciences of the United States of America 88 (7): 2692–6. doi:10.1073/pnas.88.7.2692. PMC 51304. PMID 1849272.
- Thomson, Linda (October 28, 2009). "Judge orders Pfizer to pay BYU $852K for suit delays". Deseret News.
- BYU Chemistry Department bio of Simmons
- Zoom business info collection of articles on Simmons
- Utah Science medals awards including a short bio of Simmons